Phase 3 LITESPARK-022: Pembrolizumab (pembro) plus hypoxia-inducible factor 2α (HIF-2α) inhibitor belzutifan as adjuvant treatment for clear cell renal cell carcinoma (ccRCC). Toni K. Choueiri , Jens ...

A new review was published in Volume 16 of Oncotarget on June 17, 2025, titled "Optimizing enfortumab vedotin plus pembrolizumab therapy." ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Pembrolizumab, an immune checkpoint inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with resectable locally advanced head and neck squamous ...

Pembrolizumab, an anti–programmed death 1 (PD-1) antibody, was approved in 2021 as adjuvant treatment for patients with renal-cell carcinoma who were at an intermediate-to-high or high risk for ...

Neoadjuvant cobolimab and dostarlimab followed by surgery and adjuvant dostarlimab may confer benefits over perioperative pembrolizumab in patients with high-risk, resectable melanoma.

Pembrolizumab was given for 16 additional cycles postoperatively, concurrently with adjuvant chemoradiation (45 Gy) and 5 cycles of capecitabine (825 mg/m2 days 1-14 during cycles 3, 6 and 7; 625 ...

Pembrolizumab demonstrated promising efficacy and safety in anaplastic thyroid cancer based on pooled survival and tumor ...

A first-line regimen involving pembrolizumab (Keytruda) and olaparib (Lynparza) significantly reduced the risk of disease progression or death in ovarian cancer patients without BRCA mutations, a ...

Standard first-line chemotherapy for endometrial cancer is paclitaxel plus carboplatin. The benefit of adding pembrolizumab to chemotherapy remains unclear. In this double-blind, placebo ...

Cite this: Pembrolizumab Not So Hot (Yet) for Breast Cancer - Medscape - Dec 11, 2015. Authors and Disclosures. Authors and Disclosures Journalist Neil Osterweil.